Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 maintenance study of subcutaneous vedolizumab in moderately to severely active ulcerative colitis after response to open-label intravenous vedolizumab
MOH_2017-01-05_000034Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vedolizumab in autoimmune colitis (3 arms), sponsored by Takeda. Primary endpoint: Clinical remission. Started Jan 2016; status: completed.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2017-01-05_000034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-01-05_000034.